Colorado PDAB Considering UPL For Cosentyx, Stelara

By Luke Zarzecki / July 3, 2024 at 3:38 PM
If history repeats itself, Colorado’s prescription drug affordability board (PDAB) could see more lawsuits after the board voted Wednesday (July 3) to initiate the process of establishing upper payment limits (UPL) for Janssen Biotech’s Stelara and Novartis’ Cosentyx. Colorado’s PDAB is the furthest along compared to other state PDABs, with the drugs as the second and third treatments to be considered for a UPL in the state and the country. Colorado’s PDAB voted in February to consider a UPL for...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.